Chronic Active Epstein-Barr Virus (CAEBV)
Rare persistent EBV infection causing severe immune dysregulation. MSC therapy modulates the aberrant immune response driving viral persistence and organ damage.
Chronic Active Epstein-Barr Virus disease (CAEBV) is a rare but serious condition in which EBV infection persists in T cells or NK cells (rather than B cells, as in typical EBV infection), driving a severe, progressive immune dysregulation syndrome. CAEBV is characterized by persistent fever, lymphadenopathy, hepatosplenomegaly, and — in advanced cases — hemophagocytic lymphohistiocytosis (HLH), lymphoma, or organ failure.
CAEBV predominantly affects individuals of Asian, Native American, and Latin American descent, suggesting a genetic susceptibility component. Standard treatment is limited and unsatisfactory: immunosuppressive regimens provide temporary benefit, and hematopoietic stem cell transplantation (HSCT) is the only potentially curative option — but carries significant transplant-related mortality and is not available to most patients.
MSC therapy is being explored as an adjunctive immune-modulatory strategy in CAEBV — targeting the aberrant immune dysregulation driving disease progression while potentially supporting the patient toward more definitive treatment or sustained stability.
MSCs suppress the hyperactivated immune response that characterizes CAEBV — reducing the cytokine storm components (IFN-γ, TNF-α, IL-6, IL-10) that drive hemophagocytosis and organ damage. Through direct inhibition of NK and T-cell hyperactivation and expansion of regulatory T-cell populations, MSC infusion has shown potential to break the self-amplifying inflammatory cycle of CAEBV.
In published case reports and small series, MSC infusion in patients with HLH and CAEBV-associated immune dysregulation has produced transient improvement in ferritin levels, temperature normalization, and reduction in cytopenias — providing a therapeutic bridge in patients awaiting HSCT or managing disease outside transplant-eligible criteria.
True Regen evaluates CAEBV patients with EBV viral load, NK/T-cell immunophenotyping, ferritin, LDH, and organ function panel before treatment. Each case is individually reviewed by Regen Cord's clinical team given the complexity of this diagnosis.
- Reduction in EBV viral load
- Decreased ferritin and inflammatory cytokine levels
- Improved cytopenias (anemia, thrombocytopenia)
- Reduced fever burden and constitutional symptoms
- Improved immune regulation markers
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.